Immunomodulation with Iguratimod: A Novel molecule for the management of rheumatoid arthritis

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory condition that results in release of various inflammatory mediators which causes destruction of bone, cartilage, and tendons. RA affects less than 1% population worldwide. The treatment of RA includes disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. The remission rates of RA with available treatment are low. Iguratimod (IGU) is newly developed molecule, approved for its use in Japan and China is reported to significantly reduce the effects of various inflammatory mediators that results in progression of RA. IGU through its anti-inflammatory, immunomodulatory, and osteoprotective mechanisms may result in overall management of RA. IGU is reported to be safe and effective in various clinical trials as a monotherapy or when combined with other DMARDs. The current review summarizes various effects of IGU and considers it as a promising therapeutic option for RA management.